Question explored with the scientific record
Conversation so far
- 1 Is ACI-24.060 a promising drug for Alzheimer’s
- 2 What phase is ACI-24.060 in, and when are results expected?
Answered on this page ↓
What phase is ACI-24.060 in, and when are results expected?
The short version: the records don't say. No phase and no results date for ACI-24.060 appears in anything retrieved.
The only human trial record here is for the older ACI-24, not ACI-24.060. It describes a Phase I/II, double-blind, randomized, placebo-controlled study in mild to moderate Alzheimer's, about 198 participants planned, with roughly 12 months of treatment and 24 months of follow-up [1]. Its primary endpoints were safety, tolerability, antibody titers, and a cognitive score [1]. That review was published in 2016 and lists the trial as ongoing at the time [1]. It tells you nothing about where ACI-24.060 sits now, and nothing about when its results are due.
The other three records are strays: tau phosphorylation [2], proton pump inhibitors and dementia [3], and alpha-synuclein PET tracers [4]. None mentions ACI-24.060.
I won't guess a phase or a date. Trial registries and company announcements are where that lives, and they are not in front of me.
My call: the phase and expected readout date for ACI-24.060 are not established by this evidence; what is documented is only an earlier ACI-24 Phase I/II trial, ongoing as of 2016 [1]. Confidence: high that the records don't answer it, not clear on the actual phase.
Sources used 4
-
Monophosphoryl Lipid-A: A Promising Tool for Alzheimer’s Disease Toll
A comprehensive review synthesizing preclinical and early clinical evidence that monophosphoryl lipid A (MPL) can modulate Toll-like receptor 4 signaling to boost microglial amyloid-beta clearance with limited inflammation, improving Alzheimer’s disease pathology in animal model…
DOI: 10.3233/jad-151183 -
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies
A comprehensive review of tau phosphorylation in Alzheimer's disease and other tauopathies, detailing (i) physiologic and pathologic phosphorylation of tau, (ii) phosphorylation-based biomarkers in CSF and plasma including p-tau181, p-tau217, and p-tau231, (iii) Braak staging an…
DOI: 10.1186/s13024-021-00460-5 -
Proton pump inhibitor use and risk of dementia
In a meta-analysis of six cohort studies, proton pump inhibitor use was not statistically associated with dementia (pooled RR 1.23, 95% CI 0.90-1.67) or Alzheimer's disease (pooled RR 1.01, 95% CI 0.78-1.32), though heterogeneity was high.
DOI: 10.1097/md.0000000000014422 -
Current Status of α-Synuclein Biomarkers and the Need for α-Synuclein PET Tracers
This review surveys the current landscape of α-synuclein biomarkers and underscores the urgent need for α-synuclein PET tracers, detailing the limitations of existing fluid and tissue biomarkers and evaluating emerging imaging approaches and tracers.
DOI: 10.3390/cells14161272